Search

Your search keyword '"Mahajan, Ajaykumar"' showing total 30 results

Search Constraints

Start Over You searched for: Author "Mahajan, Ajaykumar" Remove constraint Author: "Mahajan, Ajaykumar"
30 results on '"Mahajan, Ajaykumar"'

Search Results

1. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

2. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

3. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

6. Clinical evaluation of the Hydra self-expanding transcatheter aortic valve:6 month results from the GENESIS trial

7. Clinical evaluation of the Hydra self‐expanding transcatheter aortic valve: 6 month results from the GENESIS trial

8. First-in-human evaluation of a novel balloon-expandable transcatheter heart valve in patients with severe symptomatic native aortic stenosis: the MyVal-1 study

9. Evaluation of Balloon Expandable Transcatheter Heart Valve in the Treatment of Severe Symptomatic Native Aortic Stenosis: The First-in-human MyVal-1 Study

10. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes

11. Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome ODYSSEY OUTCOMES Trial

12. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events The ODYSSEY OUTCOMES Trial

13. Effects of alirocumab on types of myocardial infarction : insights from the ODYSSEY OUTCOMES trial

14. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

15. Three-year clinical and two-year multimodality imaging outcomes of a thin-strut sirolimus-eluting bioresorbable vascular scaffold: MeRes-1 trial

16. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

18. Corrigendum to “Cardiological Society of India position statement on management of heart failure in India” [Indian Heart J 70 (S1) (2018) S1–S72]

19. TCT-64 Two-Year Clinical and Imaging Outcomes of Thin Strut Sirolimus-Eluting Bioresorbable Vascular Scaffolds in De Novo Coronary Artery Lesions: The MeRes-1 Trial

20. CSI position statement on management of heart failure in India

22. Is atrial fibrillation an independent predictor of prosthetic heart valve thrombosis

23. First-in-human evaluation of a novel poly-L-lactide based sirolimus-eluting bioresorbable vascular scaffold for the treatment of de novo native coronary artery lesions: MeRes-1 trial

24. TCTAP A-058 Favorable Outcomes for Systemic Pharmacokinetic Study of Sirolimus-eluting Bioresorbable Vascular Scaffold System in Treating De Novo Native Coronary Artery Lesion: A Sub Study of MeRes-1 Trial

25. TCTAP A-003 First-in-human Evaluation of a Novel Poly-L-lactide Based Sirolimus-eluting Bioresorbable Vascular Scaffold for the Treatment of De Novo Native Coronary Artery Lesions: MeRes-1 Trial

26. CRT-700.01 Favourable Outcomes for Systemic Pharmacokinetic Study of Sirolimus-Eluting BioResorbable Vascular Scaffold System in Treating de novo Native Coronary Artery Lesion: A Sub Study of MeRes-1 Trial

30. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Catalog

Books, media, physical & digital resources